Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

Cri-report - Research Report On China's Hypolipidemic Drug Market, 2012-2013

(CRI-report) -As the population further aging in China, the proportion of diseases such as hypertension caused by hyperlipidemia in cardiovascular diseases of the elderly presents an increasing trend year by year which severely threatens the life safety of people. Therefore, the search for hypolipidemic drugs with significant efficacy, safety and reliability has been a long-term and quite popular research subject in the pharmaceutical field.

According to surveys, the overall morbidity rate of dyslipidemia groups aged 18 and above is over 20% in China, and total patients are over 200 million nationwide. Blood lipid levels and morbidity rate of dyslipidemia of Chinese people are still lower than that in most developed countries. However, with the development of China's economy, improvement in people's living standards and changes in lifestyle, the morbidity rate of dyslipidemia gradually rises. Meanwhile, diabetes and metabolic syndrome closely related to dyslipidemia are also common in China.

According to market research, the market size of China's hypolipidemic drugs exceeded CNY 12 billion in 2011, with an annual growth rate of over 15 %.

Full report: www.cri-report.com/drug/8552-research-re...

At present, blood lipid controlling drugs in the Chinese market are mainly divided into five categories: statins, fibrates, nicotinic acids, resins and cholesterol absorption inhibitors, also including some other drugs. Statins and fibrates occupy the largest market share in the Chinese market, and applications of other drugs are relatively a few. In terms of the market share of major varieties, the total market share of the top 5 hypolipidemic drug varieties in China was over 80% in 2009. Among them, the top 4 products all were statins (respectively: Atorvastatin, Simvastatin, Pravastatin and Fluvastatin), which occupied nearly 80% of the market share. In 2011, the market share of the top 5 varieties in China's hypolipidemic market was 82.64%. Among them, the top 4 products were still statins (respectively: Atorvastatin, Simvastatin, Pravastatin and Fluvastatin), which accounted for 78% of the share. It is obvious that statin products are main forces in hyperlipidemia treatment drug market of China. Statins are always in leading positions in China's hypolipidemic drug market. Because of excellent effects, little side effects and other multiple effects including lowering overall mortality rate, statin drugs are major drugs in the joint lipid-lowering program, thus occupying a most advantageous position clinically.

The overall performance of China's hypolipidemic drugs in the drug market is better than that of the entire drug and cardiovascular system drug markets, showing a strong growth momentum. The expansion speed of hypolipidemic drug market is evidently higher than that of the cardiovascular drug market, and the proportion in cardiovascular system drugs gradually rises.

More following information can be acquired through this report:

-Status Quo of China's Hypolipidemic Drug Market

-Status Quo of China's Statin Drug Market

-Market Size of Major Varieties of China's Hypolipidemic Drugs

- Competition in China's Hypolipidemic Drug Market

-Market Prices of Major Hypolipidemic Drugs in China

- Prediction on Development of China's Hypolipidemic Drugs

Following people are recommended to buy this report:

- Pharmaceutical Enterprises

- Pharmaceutical Trade Enterprises

-Hospitals

- Investors/Research Institutions Focusing on China's Pharmaceutical industry

Full report: www.cri-report.com/drug/8552-research-re...